Why Is ALKERMES PLC (ALKS) Stock Moving Today?

ALKS stock fell 7.11% to $43.39 in today's session, driven by a mix of early intraday volatility and investor reaction to recent developments. The stock opened with a modest 0.8% gap up at $43.75 but quickly reversed course, falling to a session low of $43.74 within minutes. The decline followed a series of recent insider sales and ongoing mixed sentiment from analysts, despite positive Phase 1b trial results for Alkermes' ADHD drug candidate ALKS 7290.

What Happened

Alkermes announced positive Phase 1b results for ALKS 7290, showing clinically meaningful improvements in ADHD symptoms with no serious treatment-emergent adverse events. The company plans to move to a Phase 2 trial involving 312 adults, with data expected in 2027. This information was disclosed in a Form 8-K filed on September 21, 2026, under Regulation FD and other events. The news was initially met with optimism, as reflected in a headline from Investing.com, but the stock's performance suggests a more cautious investor response.

In the days leading up to the drop, several analysts raised price targets for ALKS, including JPMorgan, Baird, and Piper Sandler, though JPMorgan maintained a neutral stance. Meanwhile, three executives at Alkermes sold shares in the past two weeks, totaling $4.2 million in disclosed transactions. These insider sales may have contributed to investor uncertainty. Additionally, the company's Q3 sales guidance of $450 million to $470 million came in below the estimated $472.75 million, signaling potential near-term challenges.

What The Data Shows

The stock has been volatile in recent weeks, closing 0.6% lower over the last eight sessions, from $49.61 to $49.30. The current session saw a high of $47.19 and a low of $43.74, with the stock closing at $47.00. Despite the intraday high, volume remained at 0.0M shares, which is 0.0x the 3-month average. The stock is trading within its 52-week range of $26.99 to $55.67, with a market cap of $7.3 billion and a P/E ratio of 111.8.

What To Watch

Investors should monitor the company's Phase 2 trial data expected in 2027 and the scheduled Q3 earnings report for further insight into the drug's development and financial performance.

Why is ALKS stock moving today?

ALKERMES PLC (ALKS) is drawing unusual attention today. Our newswire has captured 1 story on ALKS across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 50/100). The most recent driver: "Alkermes Q3 2026 Earnings Preview" (Seeking Alpha).

Is ALKS a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of ALKS coverage reads 50/100 over 1 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.